Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | CTSH | P09668 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | CALCR | P30988 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200318 | 1.00 | CTSL (0.49) | CTSLCTSSCTSKCTSHMC4R | |
| SCHEMBL30910841 | 0.93 | CTSL (0.52) | CTSLCTSSCTSKCTSHMC4R | |
| SCHEMBL30366772 | 0.93 | MC4R (0.47) | MC4RF2OPRM1OPRD1CALCRL | |
| SCHEMBL31050545 | 0.89 | MC4R (0.53) | CTSLCTSSCTSKCTSHMC4R | |
| SCHEMBL30015314 | 0.89 | REN (0.53) | APLNR | |
| SCHEMBL30366623 | 0.87 | ACE (0.48) | OPRM1OPRD1CALCRL | |
| SCHEMBL31437190 | 0.87 | CTSL (0.62) | CTSLCTSSCTSKCTSHMC4R | |
| SCHEMBL30456911 | 0.85 | APLNR (0.52) | CTSLCTSSCTSKCTSHAPLNR | |
| SCHEMBL31505801 | 0.84 | CTSL (0.56) | CTSLCTSSCTSKCTSHMC4R | |
| SCHEMBL30969039 | 0.84 | APLNR (0.55) | CTSLCTSSCTSKCTSHAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2025-12-04 | — | — | US | claimed |
| US-12472177-B2 | Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2025-11-18 | — | — | US | claimed |
| US-20250312463-A1 | AUGMENTED PEPTIDE COMPOSITIONS AND METHODS | Neo7Bioscience, Inc. (US) | 2025-10-09 | — | — | US | claimed |
| CN-120198276-A | Image cartoon style migration method and system based on Puff-Net | 南京邮电大学 | 2025-06-24 | — | — | CN | claimed |
| CN-119919641-A | Method for extracting morphological and phenotypic information of plant | 安徽农业大学 | 2025-05-02 | — | — | CN | claimed |
| CN-119904101-A | Method for dynamically evaluating critical rainfall of ponding point and predicting ponding risk | 合肥泽众城市智能科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| US-20250127843-A1 | ADRENOCORTICOTROPIC HORMONE PEPTIDE COMPOSITIONS AND METHODS OF USE | FERRING B.V. (NL) | 2025-04-24 | — | — | US | claimed |
| CN-119784234-A | Natural resource project budget management system based on performance big data | 安徽省第二测绘院 | 2025-04-08 | — | — | CN | claimed |
| CN-119514252-A | Efficient structure optimization method for improving energy storage density of flywheel rotor | 南京工业大学 | 2025-02-25 | — | — | CN | claimed |
| WO-2025037993-A1 | DOSAGE FORM FOR PEPTIDE AGENTS | MAJEWSKI FILIP (PL) | 2025-02-20 | — | — | WO | claimed |
| CN-115345366-A | Moderate-level cooperative control method for pedestrian flow of large passenger transport hub | 宁波工程学院 | 2022-11-15 | — | — | CN | claimed |
| CN-115243688-A | Bicyclic compounds and methods of their use in treating PITT HOPKINS syndrome | 诺仁制药有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-115000969-A | Hybrid power flow controller planning configuration method considering wind power integration | 国网河北省电力有限公司经济技术研究院 | 2022-09-02 | — | — | CN | claimed |
| EP-4048264-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | Neuren Pharmaceuticals Limited (NZ) | 2022-08-31 | — | — | EP | claimed |
| CN-110350548-B | UPFC-based power system safety and stability online prevention control method, device and system | 国电南瑞科技股份有限公司 | 2022-08-30 | — | — | CN | claimed |
| WO-2022173315-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2022-08-18 | — | — | WO | claimed |
| US-11378073-B2 | Estimation device and valve control device | SHIMADZU CORPORATION (JP) | 2022-07-05 | — | — | US | claimed |
| CN-112862259-B | Development and evaluation method for three-dimensional exploitation of sea-land transition phase shale reservoir | 西南石油大学 | 2022-07-01 | — | — | CN | claimed |
| CN-114384610-A | Hail short-term landing area forecasting method and device, electronic equipment and storage medium | 中国人民解放军94201部队 | 2022-04-22 | — | — | CN | claimed |
| US-20030027760-A1 | Composition and methods to improve neural outcome | ENDOCRINZ LIMITED (NZ) | 2003-02-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | CTSL 2352/4885CTSS 3168/4885CTSK 3044/4885 |
| US-20250127843-A1 | ADRENOCORTICOTROPIC HORMONE PEPTIDE COMPOSITIONS AND METHODS OF USE | MC2R, CRH, NR5A1 | CTSL 2881/4885CTSS 4787/4885CTSK 4555/4885 |
| US-12472177-B2 | Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome | QPCT, GRIA2, GGPS1 | CTSL 2352/4885CTSS 3168/4885CTSK 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.